Rationale for LDH-targeted cancer immunotherapy.

Tina B S Miholjcic, Heloise Halse, Mélodie Bonvalet, Amélie Bigorgne, Mathieu Rouanne, Laurent Dercle, Vishnu Shankar, Aurélien Marabelle

European journal of cancer (Oxford, England : 1990) 2023 Mar

filter terms:

Immunotherapies have significantly improved the survival of patients in many cancers over the last decade. However, primary and secondary resistances are encountered in most patients. Unravelling resistance mechanisms to cancer immunotherapies is an area of active investigation. Elevated levels of circulating enzyme lactate dehydrogenase (LDH) have been historically considered in oncology as a marker of bad prognosis, usually attributed to elevated tumour burden and cancer metabolism. Recent evidence suggests that elevated LDH levels could be independent from tumour burden and contain a negative predictive value, which could help in guiding treatment strategies in immuno-oncology. In this review, we decipher the rationale supporting the potential of LDH-targeted therapeutic strategies to tackle the direct immunosuppressive effects of LDH on a wide range of immune cells, and enhance the survival of patients treated with cancer immunotherapies. Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Citation

Tina B S Miholjcic, Heloise Halse, Mélodie Bonvalet, Amélie Bigorgne, Mathieu Rouanne, Laurent Dercle, Vishnu Shankar, Aurélien Marabelle. Rationale for LDH-targeted cancer immunotherapy. European journal of cancer (Oxford, England : 1990). 2023 Mar;181:166-178